Nachrichten zu 4D Molecular Therapeutics

Startseite > Aktien > 4D Molecular Therapeutics > Nachrichten

4D Molecular Therapeutics Aktie

Aktie

ISIN: US35104E1001 WKN: A2PS5P SYM: FDMT Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

16,250

USD

+2,14 %

+0,340 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

13.09.24

16,240

USD

1.400 STK

Briefkurs

13.09.24

16,250

USD

200 STK

4D Molecular Therapeutics Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm 12.09.24 · Business Wire (engl.) · 4D Molecular Therapeutics
4DMT Announces Presentations at Upcoming Retina Conferences 05.09.24 · globenewswire · 4D Molecular Therapeutics
4DMT to Participate in the 2024 Cantor Global Healthcare Conference 03.09.24 · globenewswire · 4D Molecular Therapeutics
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 27.08.24 · globenewswire · 4D Molecular Therapeutics
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 12.08.24 · globenewswire · 4D Molecular Therapeutics
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights 08.08.24 · globenewswire · 4D Molecular Therapeutics
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board 05.08.24 · globenewswire · 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings 29.07.24 · Business Wire (engl.) · 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings 21.07.24 · Business Wire (engl.) · 4D Molecular Therapeutics
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm 17.07.24 · Business Wire (engl.) · 4D Molecular Therapeutics
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity 17.07.24 · globenewswire · 4D Molecular Therapeutics
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy 24.06.24 · globenewswire · 4D Molecular Therapeutics

1
2
3
…
4

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud ... 100 Leser

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 572 Leser
4DMT to Participate in the 2024 Cantor Global Healthcare Conference 144 Leser
4DMT Announces Presentations at Upcoming Retina Conferences 124 Leser
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud ... 100 Leser

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud ... 620 Leser
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 572 Leser
4DMT Announces Presentations at ARVO 2024 Annual Meeting 312 Leser
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights 304 Leser
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 272 Leser
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation ... 208 Leser
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock 188 Leser
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine ... 176 Leser
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for ... 160 Leser
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic ... 148 Leser